Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings.
Date of review: March 2020
For questions, please contact email@example.com
Interventions of Interest:
- Crizanlizumab (Adakveo®, Novartis)
- Voxelotor (Oxbryta®, Global Blood Therapeutics)
- L-gluatmine (Endari, Emmaus Medical)
View the Key Stakeholders List.
Below you will find the final documents from the assessment review process: